125 related articles for article (PubMed ID: 27538783)
1. Using supply side evidence to inform oral artemisinin monotherapy replacement in Myanmar: a case study.
Khin HS; Aung T; Aung M; Thi A; Boxshall M; ; White C
Malar J; 2016 Aug; 15(1):418. PubMed ID: 27538783
[TBL] [Abstract][Full Text] [Related]
2. Oral artemisinin monotherapy removal from the private sector in Eastern Myanmar between 2012 and 2014.
Khin HS; Aung T; Thi A; White C;
Malar J; 2016 May; 15(1):286. PubMed ID: 27216408
[TBL] [Abstract][Full Text] [Related]
3. Who continues to stock oral artemisinin monotherapy? Results of a provider survey in Myanmar.
Thein ST; Sudhinaraset M; Khin HS; McFarland W; Aung T
Malar J; 2016 Jun; 15():334. PubMed ID: 27333781
[TBL] [Abstract][Full Text] [Related]
4. Availability and quality of anti-malarials among private sector outlets in Myanmar in 2012: results from a large, community-based, cross-sectional survey before a large-scale intervention.
Khin HS; Chen I; White C; Sudhinaraset M; McFarland W; Littrell M; Montagu D; Aung T
Malar J; 2015 Jul; 14():269. PubMed ID: 26169498
[TBL] [Abstract][Full Text] [Related]
5. Insights into the availability and distribution of oral artemisinin monotherapy in Myanmar: evidence from a nationally representative outlet survey.
; Thein ST; Khin HSS; Thi A
Malar J; 2017 Apr; 16(1):170. PubMed ID: 28438145
[TBL] [Abstract][Full Text] [Related]
6. Anti-malarial landscape in Myanmar: results from a nationally representative survey among community health workers and the private sector outlets in 2015/2016.
; Thein ST; Khin HSS; Thi A
Malar J; 2017 Apr; 16(1):129. PubMed ID: 28438197
[TBL] [Abstract][Full Text] [Related]
7. Private sector opportunities and threats to achieving malaria elimination in the Greater Mekong Subregion: results from malaria outlet surveys in Cambodia, the Lao PDR, Myanmar, and Thailand.
; Phok S; Phanalasy S; Thein ST; Likhitsup A
Malar J; 2017 May; 16(1):180. PubMed ID: 28464945
[TBL] [Abstract][Full Text] [Related]
8. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries.
O'Connell KA; Gatakaa H; Poyer S; Njogu J; Evance I; Munroe E; Solomon T; Goodman C; Hanson K; Zinsou C; Akulayi L; Raharinjatovo J; Arogundade E; Buyungo P; Mpasela F; Adjibabi CB; Agbango JA; Ramarosandratana BF; Coker B; Rubahika D; Hamainza B; Chapman S; Shewchuk T; Chavasse D
Malar J; 2011 Oct; 10():326. PubMed ID: 22039838
[TBL] [Abstract][Full Text] [Related]
9. Case management of malaria fever in Cambodia: results from national anti-malarial outlet and household surveys.
Littrell M; Gatakaa H; Phok S; Allen H; Yeung S; Chuor CM; Dysoley L; Socheat D; Spiers A; White C; Shewchuk T; Chavasse D; O'Connell KA
Malar J; 2011 Oct; 10():328. PubMed ID: 22039922
[TBL] [Abstract][Full Text] [Related]
10. Assessment of household ownership of bed nets in areas with and without artemisinin resistance containment measures in Myanmar.
Maung TM; Oo T; Wai KT; Hlaing T; Owiti P; Kumar B; Shewade HD; Zachariah R; Thi A
Infect Dis Poverty; 2018 Mar; 7(1):19. PubMed ID: 29571301
[TBL] [Abstract][Full Text] [Related]
11. What happened to anti-malarial markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African countries under continuation of the private sector co-payment mechanism.
; Tougher S; Hanson K; Goodman C
Malar J; 2017 Apr; 16(1):173. PubMed ID: 28441956
[TBL] [Abstract][Full Text] [Related]
12. When it just won't go away: oral artemisinin monotherapy in Nigeria, threatening lives, threatening progress.
; Ujuju C; Anyanti J; Newton PN; Ntadom G
Malar J; 2017 Dec; 16(1):489. PubMed ID: 29246208
[TBL] [Abstract][Full Text] [Related]
13. The ACTwatch project: methods to describe anti-malarial markets in seven countries.
Shewchuk T; O'Connell KA; Goodman C; Hanson K; Chapman S; Chavasse D
Malar J; 2011 Oct; 10():325. PubMed ID: 22039780
[TBL] [Abstract][Full Text] [Related]
14. Prescription practices and availability of artemisinin monotherapy in India: where do we stand?
Mishra N; Anvikar AR; Shah NK; Kamal VK; Sharma SK; Srivastava HC; Das MK; Pradhan K; Kumar H; Gupta YK; Gupta P; Dash AP; Valecha N
Malar J; 2011 Dec; 10():360. PubMed ID: 22166073
[TBL] [Abstract][Full Text] [Related]
15. The malaria testing and treatment landscape in mainland Tanzania, 2016.
; Michael D; Mkunde SP
Malar J; 2017 Apr; 16(1):202. PubMed ID: 28521811
[TBL] [Abstract][Full Text] [Related]
16. Improving uptake and use of malaria rapid diagnostic tests in the context of artemisinin drug resistance containment in eastern Myanmar: an evaluation of incentive schemes among informal private healthcare providers.
Aung T; White C; Montagu D; McFarland W; Hlaing T; Khin HS; San AK; Briegleb C; Chen I; Sudhinaraset M
Malar J; 2015 Mar; 14():105. PubMed ID: 25885581
[TBL] [Abstract][Full Text] [Related]
17. Evidence of successful malaria case management policy implementation in Cambodia: results from national ACTwatch outlet surveys.
; Novotny J; Singh A; Dysoley L; Sovannaroth S; Rekol H
Malar J; 2016 Apr; 15():194. PubMed ID: 27059952
[TBL] [Abstract][Full Text] [Related]
18. Evidence on anti-malarial and diagnostic markets in Cambodia to guide malaria elimination strategies and policies.
; Phok S; Lek D
Malar J; 2017 Apr; 16(1):171. PubMed ID: 28438204
[TBL] [Abstract][Full Text] [Related]
19. The malaria testing and treatment landscape in Benin.
; Zinsou C; Cherifath AB
Malar J; 2017 Apr; 16(1):174. PubMed ID: 28446236
[TBL] [Abstract][Full Text] [Related]
20. Access to artemisinin-based combination therapies and other anti-malarial drugs in Kinshasa.
Nkoli Mandoko P; Sinou V; Moke Mbongi D; Ngoyi Mumba D; Kahunu Mesia G; Losimba Likwela J; Bi Shamamba Karhemere S; Muepu Tshilolo L; Tamfum Muyembe JJ; Parzy D
Med Mal Infect; 2018 Jun; 48(4):269-277. PubMed ID: 29530387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
